Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

CoreLab Partners

With over 36 years of global experience, CoreLab Partners provides its clinical trial sponsors best-in-class centralized cardiac safety & efficacy services and independent medical image assessment solutions; all designed to facilitate successful new drug development in the pharmaceutical, biotechnology and medical device market sectors.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Genesis Research Group logo

Genesis Research Group

Genesis Research Group empowers life science companies to innovate differently by fundamentally transforming the way they engage with research partners. Through the integration of robust stakeholder insights (RPR), data-agnostic expertise,…

View Profile

Market access, Regulatory affairs, Research and development

Company Details

CoreLab Partners
Elisabethstrasse 91, 80797 Munich, Germany
+49 89 2024 4497 0
Contact CoreLab Partners
Website

 Latest Content from PMHub 

Onyx Health Joins Forces with Rare Disease Specialists Actigen

Press Releases | April 14, 2022 | Onyx Health

Onyx Health will be working with Actigen to raise awareness of their innovative clinical trial work in rare diseases and the need to develop new treatment solutions.

From Vision to Action: Medical Affairs’ Time to Lead is Now – Key Themes and Takeaways From the 2022 Medical Affairs Professional Society (MAPS) Global Annual Meeting

Press Releases | April 14, 2022 | Nucleus Global

Nucleus Global’s Luis Perez shares his thoughts on this year’s meeting

Importance of Diversity in Pharma and Clinical Trials

White Papers and Resources | April 13, 2022 | Impetus Digital

No matter which sector you work in, diversity and inclusion are must-haves!

Launch excellence

Press Releases | April 12, 2022 | Lucid Group Communications Limited

In the April edition of PME, Cheryl Harrison Doyle, Global Asset Strategy Director at Lucid Group discusses the need to take a more considered, outcomes-led approach when launching new medicines...

Case Study: Reducing Travel-Related Emissions and Costs Through Virtual Events

White Papers and Resources | April 11, 2022 | Impetus Digital

In early 2021, due to COVID-19-related safety concerns and travel and social distancing restrictions, our client needed help to “virtualize” their nationwide, multi-day, multi-business unit internal event with 375 attendees....

Meet The Lucid Group Talent Team

Videos and Podcasts | April 11, 2022 | Lucid Group Communications Limited

Meet our talent team, they're here to help and transform your career.We have some exciting roles at all levels in account management and medical writing.If you choose to take your...

Celebrating the new UK rare diseases framework

White Papers and Resources | April 8, 2022 | Dice Medical Communications

Dice's take on the importance of the rare diseases framework

Top 10 Reasons Why Virtual Collaboration and Medical Education Will Persist in the New Normal

Videos and Podcasts | April 8, 2022 | Impetus Digital

A version of this article was previously published on Pharmaphorum.There is not a single industry that has been left untouched by COVID-19. While the effects of the pandemic have been devastating...

Data-Driven Approaches for Neurorecovery

Videos and Podcasts | April 7, 2022 | Impetus Digital

Yotam Drechsler (Co-founder/CEO) and Yaron Segal (Co-founder/CINO) from BrainQ Technologies dives into the roles of Brain-Computer Interface technologies and electrophysiology measurements in aiding neurorecovery, the role of AI and machine...

UNDERSTANDING THE NEW VALUE PROPOSITION FOR THE NHS

Press Releases | April 6, 2022 | Wilmington Healthcare

Industry needs a new way of describing its commercial propositions in response to the changing NHS landscape, argues Wilmington Healthcare’s Oli Hudson. This ‘new value proposition’ needs to be reflected...